In Diabetes, Tight Blood Sugar Control Staves Off Dementia
People receiving personalized Type 2 diabetes management were 28 percent less likely to develop dementia, and 15 percent less likely to get Alzheimer's.
215 RESULTS
Sort By:
People receiving personalized Type 2 diabetes management were 28 percent less likely to develop dementia, and 15 percent less likely to get Alzheimer's.
A single-nuclei RNA-Seq study found more autophagy and chaperone gene expression in familial AD brain, more intense microglial activation in sporadic.
All endpoints were missed. Company to consider withdrawing the drug, as discussed during FDA Advisory Committee meeting.
In snoozing mice, silencing neurons dampened ion waves in the interstitial fluid and slowed the flow of solutes. Activating neurons powered CSF flow through the brain.
In a multiple sclerosis model, activated microglia reverse electron transport (RET) in their mitochondria, creating oxidative stress. Blocking RET eased pathology.
One variant promotes expression of TMEM106b in a subset of excitatory neurons, reducing their numbers. Another boosts ApoE4 in microglia.
The panel was persuaded of the antibody’s clinical efficacy and overall favorable benefit/risk ratio, although it had questions about risk in certain subgroups.
In a small dose-finding study, Roche’s new brain-shuttle-based anti-amyloid antibody mopped up nearly all plaques in three months, without triggering edema.
Inclusions in tau seed sensor cells are made of amyloid fibrils, say scientists at AD/PD 2023. In those cells, and in human neurons, a dis-aggregase shreds them.
Biogen/IONIS’s tau ASO BIIB080 dropped participants’ tau PET signal below baseline in six months of treatment, according to data from a Phase 1 study presented at AD/PD.
Perivascular macrophages both produce and react to the apolipoprotein, releasing toxic reactive oxygen species that constrict blood vessels.
At AD/PD, scientists showed 3- and 4-year amyloid immunotherapy data hinting at sustained cognitive benefits. The number of remaining participants is tiny.
The microglial receptor activates an antiviral signaling cascade. The virus downregulates TREM2 expression after infecting microglia.
Clusterin latches onto dimers of CD33 on the microglial cell surface, setting off inhibitory signaling that squelched phagocytosis.
At AD/PD, scientists placed more AD genes into microglial pathways, homed in on how TREM2 gets cleaved, debuted TREM2 agonists, and unearthed potential biomarkers.